JAMA Oncology SJR and Scopus Metrics: What the Numbers Actually Tell Authors
JAMA Oncology's Scopus profile confirms it is an elite clinical oncology journal with serious methodological credibility. The useful question is whether your paper fits that style of journal.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Quick answer: JAMA Oncology remains an elite oncology journal under Scopus-style metrics. Current Scopus-linked browser data reports a 2024 SJR of 8.377, a CiteScore of 32.6, and top-ranked standing in hematology and oncology. That confirms real authority, but the submission decision still depends on whether the manuscript is rigorous and clinically useful enough for the journal's method-heavy editorial style.
The core metric picture
Metric | 2024 value | What it tells you |
|---|---|---|
SJR | 8.377 | Prestige-weighted influence is very strong |
CiteScore | 32.6 | Four-year citation performance is elite |
SNIP | 5.665 | Field-normalized impact is also strong |
Quartile | Q1 | The journal remains firmly top-tier |
Category standing | Top-ranked in hematology and oncology | The journal has broad clinical-oncology authority |
JCR context | Impact factor 20.1 | Web of Science tells the same elite clinical story |
The useful reading is that JAMA Oncology is not only prestigious by name. Its authority holds up in prestige-weighted and longer-window citation systems as well.
What the metrics actually help with
They help clarify where the journal sits:
- below the most global oncology flagships on raw citation power
- very strong for rigorous clinical, epidemiologic, and outcomes-oriented oncology work
- especially credible when the manuscript's strength is methodological discipline plus clear clinical relevance
That is useful when the shortlist includes JAMA Oncology, JCO, Lancet Oncology, or a narrower specialty journal.
What the metrics do not answer
They do not tell you:
- whether the methods are clean enough
- whether the audience is broad enough inside oncology
- whether the paper is too narrow or too preliminary
- whether a different top oncology journal is a better tonal fit
Those are still the real submission questions.
Why the profile matters for authors
At this SJR level, JAMA Oncology can be demanding about rigor. The journal's profile reflects a specific editorial product:
- clinically useful oncology studies
- strong methodological discipline
- evidence that survives skeptical reading
- papers oncologists and evidence-minded readers keep citing
That is why the numbers are useful. They show the journal's influence is not accidental and not dependent only on the JAMA brand.
What should drive the submission decision instead
The better question is whether the manuscript is truly a JAMA Oncology paper.
That is why the better next reads are:
- JAMA Oncology submission guide
- JCO SJR and Scopus metrics
- Lancet Oncology impact factor
- Is JAMA Oncology indexed in PubMed?
If the paper is clinically interesting but methodologically rough, the metrics do not rescue the mismatch. They only explain why the journal can reject many plausible submissions quickly.
Practical verdict
JAMA Oncology has a genuine elite Scopus profile for clinical oncology. That makes it a strong target when the manuscript is methodologically sharp, clinically relevant, and broad enough to matter beyond one narrow oncology niche.
But the useful takeaway is still fit, not prestige. If the study would not withstand hard statistical and interpretive scrutiny, the metric is already warning you. A free Manusights scan is the fastest way to pressure-test that before submission.
Sources
- 1. JAMA Oncology journal browser entry, Vrije Universiteit journal publishing guide.
- 2. JAMA Oncology instructions for authors, JAMA Network.
- 3. JAMA Oncology submission guide, Manusights.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.